The proposed class action filed in Minnesota federal court by four ex-employees of Wells Fargo claims the bank violated a federal law requiring companies to prudently manage employee health and retirement plans.
The former employees say that Wells Fargo’s health plan pays inflated prices to pharmacy benefit managers, who negotiate with drugmakers, health insurance plans, and pharmacies to set prescription drug prices and decide which drugs will be included on their so-called formularies—lists of drugs covered by insurance.
The plan, for example, paid more than $69,000 for a tube of cancer medication bexarotene that cost as little as $3,750 at other pharmacies, and a markup of nearly 400% on generic “specialty drugs” used to treat certain conditions, according to Tuesday’s lawsuit.
Pharmacy benefit managers are facing increased government scrutiny over their role in escalating costs of prescription drugs.
Wells Fargo did not immediately respond to a request for comment.
The lawsuit is the latest to accuse employer-sponsored health plans of failing to negotiate lower prices for drugs on behalf of participants, as prescription drug costs continue to rise sharply in the U.S.
Johnson & Johnson is facing a proposed class action filed in New Jersey federal court in February claiming the company’s mismanagement of a health plan cost workers millions of dollars in overpayments on drugs. The company has moved to dismiss the case, arguing that its plan has actually saved participants money and that the named plaintiff lacks legal standing to sue.
Tuesday’s lawsuit proposes a nationwide class of Wells Fargo health plan participants and beneficiaries that could include tens of thousands of people, and seeks unspecified damages and statutory penalties.
—By Daniel Wiessner, Reuters
Apply to the Most Innovative Companies Awards and be recognized as an organization driving the world forward through innovation. Early-rate deadline: Friday, August 23.
